Balaxi's Q1 Losses Deepen as Revenue and Profitability Collapse
Balaxi Pharmaceuticals posted a sharp quarterly loss as revenue fell and net profit margin turned deeply negative, continuing a challenging earnings trend.
Balaxi's Q1 FY27 results show a sharp decline in revenue and a deep plunge into loss, with net profit margin falling to -8%. The company's trailing twelve-month performance offers a stark contrast.
Balaxi Pharmaceuticals' first-quarter results for FY27 reveal a significant deterioration in financial performance. The company swung to a loss as revenue declined both year-on-year and sequentially, highlighting mounting operational challenges.
The latest quarter saw revenue of ₹15.58 crore, down 6.8% from the same period last year and 23% lower than the previous quarter. More critically, profit after tax fell to a loss of ₹1.25 crore, a dramatic 725% decline year-on-year. This pushed the net profit margin deeply into negative territory at -8%, a stark drop from the 1.2% margin in Q1 FY26.
A look at the recent quarterly trajectory shows a clear pattern of weakening profitability.
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Period | Quarter ended June 2026 | Quarter ended March 2026 | Quarter ended June 2025 |
| Revenue (₹ Cr) | 15.58YoY -6.8% | 20.24 | 16.71 |
| Profit (₹ Cr) | -1.25YoY -725% | 0.16 | 0.20 |
| Net Profit Margin (%) | -8.0YoY -767% | 0.8 | 1.2 |
This sequential decline contrasts with the company's trailing twelve-month (TTM) performance, which shows a revenue of ₹79.73 crore and a profit of ₹3.7 crore, yielding a net profit margin of 4.6%. The stock's price reflects this difficult period, having fallen 49.2% over the past year.
With a net profit margin now deeply negative and revenue on a downward trend, the immediate focus for Balaxi must be on stabilizing its core operations to halt the erosion of profitability.
Live Chart
· BALAXI
(BSE)
ISIN: INE618N01022
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.